Assessing p53 in clinical contexts: Unlearned lessons and new perspectives

Journal of Pathology

Volumn 208, Issue 1, 2006, Pages 1-6

  Hall, Peter A ^a,b   McCluggage, W Glenn ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Assay; Immunohistochemistry; Mutation; p53; Pathway; Translational research

Indexed keywords

PROTEIN P53;

AMINO ACID SEQUENCE; ARTICLE; CARCINOGENESIS; DOWNSTREAM PROCESSING; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOCYTOCHEMISTRY; METHODOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; SEQUENCE ANALYSIS; TRANSLATION REGULATION;

ALLELES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN BIOSYNTHESIS; PROTEIN SPLICING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29744450338     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1913     Document Type: Article

References (55)

1. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-126.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
3. Hoffmann R, Valencia A. The life cycle of successful genes. Trends Genet 2003;19:79-81.
4. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-1703.
5. Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 1999;35:489-494.
6. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-1055.
7. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 2005;97:1023-1025.
8. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-444.
9. Soussi T. Analysis of p53 gene alterations in cancer: a critical view. In 25 Years of p53 Research, Hainaut P, Wiman KG (eds). Springer-Verlag: Berlin, 2005; 446.
10. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-330.
11. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994;172:1-4.
12. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 1985;314:633-636.
13. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nature Cell Biol 2002;4:462-467.
14. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002;21:6722-6728.
15. Courtois S, de Fromentel CC, Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 2004;23:631-638.
16. Scrable H, Sasaki T, Maier B. DeltaNp53 or p44: priming the p53 pump. Int J Biochem Cell Biol 2005;37:913-919.
17. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-137.
18. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004;18:306-319.
19. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005;26:1317-1322.
20. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005;17:631-636.
21. Hall PA, Russell SH. New perspectives on neoplasia and the RNA world. Hematol Oncol 2005;23:49-53.
22. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005;123:49-63.
23. Fu L, Minden MD, Benchimol S. Translational regulation of human p53 gene expression. EMBO J 1996;15:4392-4401.
24. Ewen ME, Miller SJ. p53 and translational control. Biochim Biophys Acta 1996;1242:181-184.
25. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003;112:29-40.
26. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-791.
27. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
28. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004;118:83-97.
29. Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, et al. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2001;2:1029-1034.
30. Stommel JM, Wahl GM. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 2005;4:411-417.
31. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 2004;13:523-535.
32. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nature Cell Biol 2004;6:665-672.
33. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, et al. The role of p53 in spontaneous and radiation induced apoptosis in the gastrointestinal tract of normal and p53 deficient mice. Cancer Res 1994;54:614-617.
34. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995;108:1843-1841.
35. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996;13:2575-2587.
36. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908.
37. Save V, Nylander K, Hall PA. Why is p53 protein stabilized in neoplasia? Some answers but many more questions? J Pathol 1998;184:348-350.
38. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-860.
39. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-872.
40. Van Dyke T. Cancer biology: sense out of missense. Nature 2005;434:287-288.
41. Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol 2005;205:206-220.
42. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005;25:6-17.
43. Soussi T, Asselian B, Hammroun D, Kato S, Ishioka C, Claustres M, Beroud C. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodological bias in mutation detection. Clin Cancer Res 2006;in press.
44. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
45. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-5484.
46. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-9587.
47. Mechanic LE, Marrogi AJ, Welsh JA, Bowman ED, Khan MA, Enewold L, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005;26:597-604.
48. Slade H, Moll UM. Mutational analysis of p53 in human tumors: immunocytochemistry. In p53 Protocols, Deb S, Deb SP (eds), Methods in Molecular Biology, vol 234. Humana Press: Clifton, NJ, 2003; 231-244.
49. Stephen CW, Helminen P, Lane DP. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol 1995;248:58-78.
50. Lane DP, Stephen CW, Midgley CA, Sparks A, Hupp TR, Daniels DA, et al. Epitope analysis of the murine p53 tumour suppressor protein. Oncogene 1996;12:2461-2466.
51. Pospisilova S, Brazda V, Amrichova J, Kamermeierova R, Palecek E, Vojtesek B. Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay. J Immunol Methods 2000;237:51-64.
52. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by immunohistochemistry. J Pathol 2005;207:251-259.
53. McCluggage WG, Connolly LE, McGregor G, Hyland PL, Hall PA. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynaecol Pathol 2005;24:307-312.
54. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259.
55. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-1184.